Novo Nordisk faces a defining year in the obesity drug market. It's off to a dramatic start

In this articleLLYNVOMaziar Mike Doustdar, CEO of Novo Nordisk, speaks in the Oval Office during an event about weight-loss drugs at the White House in Washington, DC on November 6, 2025. Andrew Caballero-Reynolds | Afp | Getty ImagesStock Chart IconStock chart iconNovo Nordisk U.S.-listed shares over the last month.The latest developments add to a thorny situation for Novo as it risks being edged out by Lilly and the growing number of people taking cheaper compounded versions of semaglutide, which are unap ...